Cue Biopharma Inc. intends to launch an IPO on the Nasdaq Capital Market.
The company plans to offer up to 8,333,333 common shares with 0.1 cent par value at a public offering price of between $6 and $8 per share. The company expects to raise proceeds of up to $50 million.
It will be listed on the Nasdaq Capital Market under the ticker CUE.
Cue Biopharma is a Cambridge, Mass.-based preclinical stage biopharmaceutical company that develops biologic drugs to treat various cancers and autoimmune disorders.
MDB Capital Group LLC and Feltl and Co. Inc. serve as underwriters in the offering.
